Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Stoop

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
NPJ Vaccines|January 30, 2021
Durable natural killer cell responses after heterologous two-dose Ebola vaccinationHelen R Wagstaffe, Giada Susannini, Rodolphe Thiébaut, et al.
The Journal of Clinical Investigation|April 22, 2020
Ebola virus glycoprotein stimulates IL-18-dependent natural killer cell responsesHelen R Wagstaffe, Elizabeth A Clutterbuck, Viki Bockstal, et al.
The Journal of Infectious Diseases|December 11, 2019
Antibody-Dependent Natural Killer Cell Activation After Ebola VaccinationHelen R Wagstaffe, Elizabeth A Clutterbuck, Viki Bockstal, et al.
Vaccines|February 26, 2026
Immunogenicity and Safety of the ExPEC9V <i>Escherichia coli</i> Vaccine Co-Administered with a High-Dose Influenza Vaccine in Older Adults: A Placebo-Controlled, Randomized, Phase 3 StudyIsabel Leroux-Roels, Tracey A Day, Sofie Deleu, et al.
Annals of the Rheumatic Diseases|April 27, 2017
Breach of autoreactive B cell tolerance by post-translationally modified proteinsJacqueline S Dekkers, Marije K Verheul, Jeroen N Stoop, et al.
NPJ Vaccines|November 30, 2022
Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against EbolaViki Bockstal, Maarten Leyssen, Dirk Heerwegh, et al.
Plos One|October 5, 2022
First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled studyViki Bockstal, Georgi Shukarev, Chelsea McLean, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
NPJ Vaccines|January 30, 2021
Durable natural killer cell responses after heterologous two-dose Ebola vaccinationHelen R Wagstaffe, Giada Susannini, Rodolphe Thiébaut, et al.
The Journal of Clinical Investigation|April 22, 2020
Ebola virus glycoprotein stimulates IL-18-dependent natural killer cell responsesHelen R Wagstaffe, Elizabeth A Clutterbuck, Viki Bockstal, et al.
The Journal of Infectious Diseases|December 11, 2019
Antibody-Dependent Natural Killer Cell Activation After Ebola VaccinationHelen R Wagstaffe, Elizabeth A Clutterbuck, Viki Bockstal, et al.
Vaccines|February 26, 2026
Immunogenicity and Safety of the ExPEC9V <i>Escherichia coli</i> Vaccine Co-Administered with a High-Dose Influenza Vaccine in Older Adults: A Placebo-Controlled, Randomized, Phase 3 StudyIsabel Leroux-Roels, Tracey A Day, Sofie Deleu, et al.
Annals of the Rheumatic Diseases|April 27, 2017
Breach of autoreactive B cell tolerance by post-translationally modified proteinsJacqueline S Dekkers, Marije K Verheul, Jeroen N Stoop, et al.
NPJ Vaccines|November 30, 2022
Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against EbolaViki Bockstal, Maarten Leyssen, Dirk Heerwegh, et al.
Plos One|October 5, 2022
First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled studyViki Bockstal, Georgi Shukarev, Chelsea McLean, et al.
Pageof 3